Timothy Rolph, Chief Scientific Officer at Akero Therapeutics, Inc. (AKRO), sold 62,500 shares at $54.76 ($3.5M) on 2025-01-27, disclosed to the SEC on 2025-01-29.
Scheduled sale ($3.5M) by Chief Scientific Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $54.76 | 13,812 | $756K | 21.7% |
| 2 | $54.76 | 13,812 | $756K | 21.7% |
| 3 | $55.62 | 5,059 | $281K | 8.1% |
| 4 | $55.62 | 5,059 | $281K | 8.1% |
| 5 | $56.97 | 12,379 | $705K | 20.2% |
| 6 | $56.97 | 12,379 |
| $705K |
| 20.2% |
| Total | $55.77 avg | 62,500 | $3.5M | 100% |
| Filing → |
| AKRO | SELL | 2025-09-10 | $1.1M | — | Filing → |
| AKRO | SELL | 2025-08-07 | $1.2M | — | Filing → |
| AKRO | SELL | 2025-07-09 | $1.2M | — | Filing → |